New radiation approach aims to tame pancreatic cancer with fewer side effects

NCT ID NCT04452357

Ongoing Disease control Sponsor: Fox Chase Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new type of radiation called pulsed low-dose-rate (PLDR) for people with pancreatic cancer that cannot be removed right away. The radiation is given in small, spaced-out bursts along with the chemotherapy drug gemcitabine. The goal is to see if this approach causes fewer stomach and bowel side effects than standard radiation. Only 12 participants are being studied to check safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PLDR radiation and gemcitabine
What this could lead to: If successful, this could lead to a safer way to shrink pancreatic tumors before surgery, with fewer side effects than standard radiation.
What could go wrong: This is a very early, small phase I trial with only 12 participants. It primarily tests safety, not effectiveness, and may not work or benefit future patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.